Result of General Meeting
22. November 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage...
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
12. November 2024 08:48 ET
|
Biodexa Pharmaceuticals PLC
November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage...
Notice of General Meeting
07. November 2024 16:30 ET
|
Biodexa Pharmaceuticals PLC
November 7, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing...
Biodexa Announces Successful Appeal of Nasdaq Delisting
15. Oktober 2024 16:15 ET
|
Biodexa Pharmaceuticals PLC
Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
04. Oktober 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...
Interim results for the six months ended June 30, 2024
26. September 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an...
ADR Ratio Change
19. September 2024 16:30 ET
|
Biodexa Pharmaceuticals PLC
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical...
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
16. September 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantFunds to Advance Development of Phase 3 Asset ...
Receipt of Nasdaq Delisting Determination - Plans to Appeal
30. August 2024 16:30 ET
|
Biodexa Pharmaceuticals PLC
August 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused...
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
23. Juli 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)...